This study suggests a 2D-LC screening method to evaluate peak purity and ensure specificity in pharmaceutical analysis, thereby promoting the safe production of medicines by detecting active pharmaceutical ingredients (API) and related substances.
John T. Lawler
Advertisement
John T. Lawler is with AbbVie Inc., Small Molecule Analytical R&D Department of AbbVie Inc., in North Chicago, Illinois.
Articles by John T. Lawler
Advertisement
Latest Updated Articles
A Standardized 2D-LC Screening Platform for Peak Purity Determination in Pharmaceutical AnalysisPublished: June 1st 2023 | Updated:
Advertisement
Advertisement
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
